Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Liver Diseases

  Free Subscription


Articles published in Gut

Retrieve available abstracts of 107 articles:
HTML format
Text format



Single Articles


    March 2018

  1. Correction: Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma.
    Gut. 2018;67:594.
    PubMed     Text format    


    February 2018
  2. CHEW V, Lee YH, Pan L, Nasir NJM, et al
    Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma.
    Gut. 2018 Feb 13. pii: gutjnl-2017-315485. doi: 10.1136/gutjnl-2017-315485.
    PubMed     Text format     Abstract available


  3. RENZULLI M, Biselli M, Brocchi S, Granito A, et al
    New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm.
    Gut. 2018 Feb 3. pii: gutjnl-2017-315384. doi: 10.1136/gutjnl-2017-315384.
    PubMed     Text format     Abstract available


  4. LEE JH, Suh JH, Choi SY, Kang HJ, et al
    Tonicity-responsive enhancer-binding protein promotes hepatocellular carcinogenesis, recurrence and metastasis.
    Gut. 2018 Feb 2. pii: gutjnl-2017-315348. doi: 10.1136/gutjnl-2017-315348.
    PubMed     Text format     Abstract available


    January 2018
  5. PERUGORRIA MJ, Esparza-Baquer A, Oakley F, Labiano I, et al
    Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage.
    Gut. 2018 Jan 27. pii: gutjnl-2017-314107. doi: 10.1136/gutjnl-2017-314107.
    PubMed     Text format     Abstract available


  6. IBRAHIM SH, Hirsova P, Gores GJ
    Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation.
    Gut. 2018 Jan 24. pii: gutjnl-2017-315691. doi: 10.1136/gutjnl-2017-315691.
    PubMed     Text format     Abstract available


  7. CHEN CJ
    Global elimination of viral hepatitis and hepatocellular carcinoma: opportunities and challenges.
    Gut. 2018 Jan 24. pii: gutjnl-2017-315407. doi: 10.1136/gutjnl-2017-315407.
    PubMed     Text format    


  8. BANTEL H, Canbay A
    Loss of KRAS control as consequence of downregulated microRNA-622 in hepatocellular carcinoma and its potential therapeutic implication.
    Gut. 2018 Jan 20. pii: gutjnl-2017-315630. doi: 10.1136/gutjnl-2017-315630.
    PubMed     Text format    


  9. YIGIT B, Boyle M, Ozler O, Erden N, et al
    Plasma cell-free DNA methylation: a liquid biomarker of hepatic fibrosis.
    Gut. 2018 Jan 20. pii: gutjnl-2017-315668. doi: 10.1136/gutjnl-2017-315668.
    PubMed     Text format    


  10. PERNES G, Lancaster GI, Murphy AJ
    Take me to the liver: adipose tissue macrophages coordinate hepatic neutrophil recruitment.
    Gut. 2018 Jan 3. pii: gutjnl-2017-315393. doi: 10.1136/gutjnl-2017-315393.
    PubMed     Text format    


  11. NEWSOME PN, Cramb R, Davison SM, Dillon JF, et al
    Guidelines on the management of abnormal liver blood tests.
    Gut. 2018;67:6-19.
    PubMed     Text format     Abstract available


  12. WIESER V, Adolph TE, Grander C, Grabherr F, et al
    Adipose type I interferon signalling protects against metabolic dysfunction.
    Gut. 2018;67:157-165.
    PubMed     Text format     Abstract available


    December 2017
  13. DIETRICH P, Koch A, Fritz V, Hartmann A, et al
    Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.
    Gut. 2017 Dec 23. pii: gutjnl-2017-315402. doi: 10.1136/gutjnl-2017-315402.
    PubMed     Text format     Abstract available


  14. CUI CP, Wong CC, Kai AK, Ho DW, et al
    SENP1 promotes hypoxia-induced cancer stemness by HIF-1alpha deSUMOylation and SENP1/HIF-1alpha positive feedback loop.
    Gut. 2017;66:2149-2159.
    PubMed     Text format     Abstract available


    November 2017
  15. GERBES A, Zoulim F, Tilg H, Dufour JF, et al
    Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma.
    Gut. 2017 Nov 17. pii: gutjnl-2017-315068. doi: 10.1136/gutjnl-2017-315068.
    PubMed     Text format     Abstract available


    October 2017
  16. MAZARD T, Boonsirikamchai P, Overman MJ, Asran MA, et al
    Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab.
    Gut. 2017 Oct 30. pii: gutjnl-2017-313786. doi: 10.1136/gutjnl-2017-313786.
    PubMed     Text format     Abstract available


  17. BIJNEN M, Josefs T, Cuijpers I, Maalsen CJ, et al
    Adipose tissue macrophages induce hepatic neutrophil recruitment and macrophage accumulation in mice.
    Gut. 2017 Oct 26. pii: gutjnl-2016-313654. doi: 10.1136/gutjnl-2016-313654.
    PubMed     Text format     Abstract available


  18. KIM GA, Lim YS, Han S, Choi J, et al
    High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
    Gut. 2017 Oct 21. pii: gutjnl-2017-314904. doi: 10.1136/gutjnl-2017-314904.
    PubMed     Text format     Abstract available


    September 2017
  19. LV Y, Qi X, He C, Wang Z, et al
    Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial.
    Gut. 2017 Sep 28. pii: gutjnl-2017-314634. doi: 10.1136/gutjnl-2017-314634.
    PubMed     Text format     Abstract available


  20. ZHOU J, Liu M, Sun H, Feng Y, et al
    Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.
    Gut. 2017 Sep 22. pii: gutjnl-2017-314032. doi: 10.1136/gutjnl-2017-314032.
    PubMed     Text format     Abstract available


  21. MUELLER C, Waldburger N, Stampfl U, Kauczor HU, et al
    Non-invasive diagnosis of hepatocellular carcinoma revisited.
    Gut. 2017 Sep 12. pii: gutjnl-2017-314981. doi: 10.1136/gutjnl-2017-314981.
    PubMed     Text format    


  22. KIM W, Khan SK, Liu Y, Xu R, et al
    Hepatic Hippo signaling inhibits protumoural microenvironment to suppress hepatocellular carcinoma.
    Gut. 2017 Sep 2. pii: gutjnl-2017-314061. doi: 10.1136/gutjnl-2017-314061.
    PubMed     Text format     Abstract available



  23. Erratum: The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B.
    Gut. 2017;66:1730.
    PubMed     Text format    


  24. BEDOSSA P, Tordjman J, Aron-Wisnewsky J, Poitou C, et al
    Systematic review of bariatric surgery liver biopsies clarifies the natural history of liver disease in patients with severe obesity.
    Gut. 2017;66:1688-1696.
    PubMed     Text format     Abstract available


    August 2017
  25. PIANO S, Bartoletti M, Tonon M, Baldassarre M, et al
    Assessment of Sepsis-3 criteria and quick SOFA in patients with cirrhosis and bacterial infections.
    Gut. 2017 Aug 31. pii: gutjnl-2017-314324. doi: 10.1136/gutjnl-2017-314324.
    PubMed     Text format     Abstract available


  26. JIAO N, Baker SS, Chapa-Rodriguez A, Liu W, et al
    Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD.
    Gut. 2017 Aug 3. pii: gutjnl-2017-314307. doi: 10.1136/gutjnl-2017-314307.
    PubMed     Text format     Abstract available


  27. HO DWH, Chan LK, Chiu YT, Xu IMJ, et al
    TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication.
    Gut. 2017;66:1496-1506.
    PubMed     Text format     Abstract available


    July 2017
  28. XIANG DM, Sun W, Ning BF, Zhou TF, et al
    The HLF/IL-6/STAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis.
    Gut. 2017 Jul 28. pii: gutjnl-2016-313392. doi: 10.1136/gutjnl-2016-313392.
    PubMed     Text format     Abstract available


  29. CORRAL JE, Mousa OY, Riegert-Johnson DL
    Massive gastrointestinal bleeding after transjugular intrahepatic portosystemic shunt (TIPS).
    Gut. 2017 Jul 7. pii: gutjnl-2017-314254. doi: 10.1136/gutjnl-2017-314254.
    PubMed     Text format    


  30. ALBANO E, Stickel F
    Targeting toll-like receptor 7/8 improves host anti-infective response in alcoholic cirrhosis.
    Gut. 2017 Jul 7. pii: gutjnl-2017-314437. doi: 10.1136/gutjnl-2017-314437.
    PubMed     Text format    


  31. HARDY T, Zeybel M, Day CP, Dipper C, et al
    Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease.
    Gut. 2017;66:1321-1328.
    PubMed     Text format     Abstract available


    June 2017
  32. ROLAS L, Boussif A, Weiss E, Letteron P, et al
    NADPH oxidase depletion in neutrophils from patients with cirrhosis and restoration via toll-like receptor 7/8 activation.
    Gut. 2017 Jun 10. pii: gutjnl-2016-313443. doi: 10.1136/gutjnl-2016-313443.
    PubMed     Text format     Abstract available


  33. JIANG RY, Yang L
    The role of hepatokines in NAFLD-related extrahepatic diseases: culprit or accomplice?
    Gut. 2017 Jun 10. pii: gutjnl-2017-314411. doi: 10.1136/gutjnl-2017-314411.
    PubMed     Text format    


  34. LYU N, Lin Y, Kong Y, Zhang Z, et al
    FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut. 2017 Jun 7. pii: gutjnl-2017-314138. doi: 10.1136/gutjnl-2017-314138.
    PubMed     Text format    


  35. WANG Z, Zhang H, Han J, Wu MC, et al
    High body mass index and the risk of hepatocellular carcinoma.
    Gut. 2017 Jun 7. pii: gutjnl-2017-314259. doi: 10.1136/gutjnl-2017-314259.
    PubMed     Text format    


  36. BAJAJ JS, Liu EJ, Kheradman R, Fagan A, et al
    Fungal dysbiosis in cirrhosis.
    Gut. 2017 Jun 3. pii: gutjnl-2016-313170. doi: 10.1136/gutjnl-2016-313170.
    PubMed     Text format     Abstract available


  37. KULLAK-UBLICK GA, Andrade RJ, Merz M, End P, et al
    Drug-induced liver injury: recent advances in diagnosis and risk assessment.
    Gut. 2017;66:1154-1164.
    PubMed     Text format     Abstract available


  38. ADAMS LA, Anstee QM, Tilg H, Targher G, et al
    Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.
    Gut. 2017;66:1138-1153.
    PubMed     Text format     Abstract available


  39. BROOKS AJ, Smith PJ, Cohen R, Collins P, et al
    UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care.
    Gut. 2017;66:988-1000.
    PubMed     Text format     Abstract available


    May 2017
  40. PANKOWICZ FP, Jarrett KE, Lagor WR, Bissig KD, et al
    CRISPR/Cas9: at the cutting edge of hepatology.
    Gut. 2017 May 9. pii: gutjnl-2016-313565. doi: 10.1136/gutjnl-2016-313565.
    PubMed     Text format     Abstract available


  41. THOMAS E
    Hepatitis B virus X protein: TRIMming antiviral defences in hepatocytes.
    Gut. 2017 May 5. pii: gutjnl-2017-314013. doi: 10.1136/gutjnl-2017-314013.
    PubMed     Text format    


  42. BREITKOPF-HEINLEIN K, Meyer C, Konig C, Gaitantzi H, et al
    BMP-9 interferes with liver regeneration and promotes liver fibrosis.
    Gut. 2017;66:939-954.
    PubMed     Text format     Abstract available


    April 2017
  43. TRIANTAFYLLOU E, Pop OT, Possamai LA, Wilhelm A, et al
    MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure.
    Gut. 2017 Apr 27. pii: gutjnl-2016-313615. doi: 10.1136/gutjnl-2016-313615.
    PubMed     Text format     Abstract available


  44. ALLWEISS L, Volz T, Giersch K, Kah J, et al
    Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo.
    Gut. 2017 Apr 20. pii: gutjnl-2016-312162. doi: 10.1136/gutjnl-2016-312162.
    PubMed     Text format     Abstract available


  45. HANIN G, Yayon N, Tzur Y, Haviv R, et al
    miRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression.
    Gut. 2017 Apr 5. pii: gutjnl-2016-312869. doi: 10.1136/gutjnl-2016-312869.
    PubMed     Text format     Abstract available


  46. PARES A
    Juan Rodes. A successful and extraordinary life of a visionary hepatologist.
    Gut. 2017;66:736.
    PubMed     Text format    


  47. LI M, He Y, Zhou Z, Ramirez T, et al
    MicroRNA-223 ameliorates alcoholic liver injury by inhibiting the IL-6-p47phox-oxidative stress pathway in neutrophils.
    Gut. 2017;66:705-715.
    PubMed     Text format     Abstract available


  48. HUR K, Toiyama Y, Okugawa Y, Ide S, et al
    Circulating microRNA-203 predicts prognosis and metastasis in human colorectal cancer.
    Gut. 2017;66:654-665.
    PubMed     Text format     Abstract available


    March 2017
  49. CARLONI V, Lulli M, Madiai S, Mello T, et al
    CHK2 overexpression and mislocalisation within mitotic structures enhances chromosomal instability and hepatocellular carcinoma progression.
    Gut. 2017 Mar 30. pii: gutjnl-2016-313114. doi: 10.1136/gutjnl-2016-313114.
    PubMed     Text format     Abstract available


  50. HAGSTROM H, Tynelius P, Rasmussen F
    High BMI in late adolescence predicts future severe liver disease and hepatocellular carcinoma: a national, population-based cohort study in 1.2 million men.
    Gut. 2017 Mar 20. pii: gutjnl-2016-313622. doi: 10.1136/gutjnl-2016-313622.
    PubMed     Text format     Abstract available


  51. PARSEUS A, Sommer N, Sommer F, Caesar R, et al
    Microbiota-induced obesity requires farnesoid X receptor.
    Gut. 2017;66:429-437.
    PubMed     Text format     Abstract available


    February 2017
  52. PARES A
    Juan Rodes. A successful and extraordinary life of a visionary hepatologist.
    Gut. 2017 Feb 24. pii: gutjnl-2017-313950. doi: 10.1136/gutjnl-2017-313950.
    PubMed     Text format    


  53. VAN RENNE N, Roca Suarez AA, Duong FH, Gondeau C, et al
    miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis.
    Gut. 2017 Feb 3. pii: gutjnl-2016-312270. doi: 10.1136/gutjnl-2016-312270.
    PubMed     Text format     Abstract available


  54. BRUNT EM, Kleiner DE
    Challenges in the hepatic histopathology in non-alcoholic fatty liver disease.
    Gut. 2017 Feb 3. pii: gutjnl-2016-313379. doi: 10.1136/gutjnl-2016-313379.
    PubMed     Text format    


  55. SINN DH, Kang D, Chang Y, Ryu S, et al
    Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study.
    Gut. 2017;66:323-329.
    PubMed     Text format     Abstract available


    January 2017
  56. ALVAREZ-SOLA G, Uriarte I, Latasa MU, Fernandez-Barrena MG, et al
    Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration.
    Gut. 2017 Jan 24. pii: gutjnl-2016-312975. doi: 10.1136/gutjnl-2016-312975.
    PubMed     Text format     Abstract available


  57. MENARD A, Aherfi S, Mokhtari S, Dhiver C, et al
    Toward chronic hepatitis C eradication in HIV-positive patients, including those cirrhotic and infected with genotype 3 viruses.
    Gut. 2017 Jan 10. pii: gutjnl-2016-313431. doi: 10.1136/gutjnl-2016-313431.
    PubMed     Text format    


  58. IKENAGA N, Peng ZW, Vaid KA, Liu SB, et al
    Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal.
    Gut. 2017 Jan 10. pii: gutjnl-2016-312473. doi: 10.1136/gutjnl-2016-312473.
    PubMed     Text format     Abstract available


  59. MAHLI A, Saugspier M, Koch A, Sommer J, et al
    ERK activation and autophagy impairment are central mediators of irinotecan-induced steatohepatitis.
    Gut. 2017 Jan 4. pii: gutjnl-2016-312485. doi: 10.1136/gutjnl-2016-312485.
    PubMed     Text format     Abstract available


  60. ROTMAN Y, Sanyal AJ
    Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.
    Gut. 2017;66:180-190.
    PubMed     Text format     Abstract available


  61. LI X, Yao W, Yuan Y, Chen P, et al
    Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.
    Gut. 2017;66:157-167.
    PubMed     Text format     Abstract available


    December 2016
  62. FERNANDEZ-BARRENA MG, Perugorria MJ, Banales JM
    Novel lncRNA T-UCR as a potential downstream driver of the Wnt/beta-catenin pathway in hepatobiliary carcinogenesis.
    Gut. 2016 Dec 16. pii: gutjnl-2016-312899. doi: 10.1136/gutjnl-2016-312899.
    PubMed     Text format    


    November 2016
  63. YU J, Yu XL, Han ZY, Cheng ZG, et al
    Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase III randomised controlled trial.
    Gut. 2016 Nov 24. pii: gutjnl-2016-312629. doi: 10.1136/gutjnl-2016-312629.
    PubMed     Text format    


  64. BOLLARD J, Miguela V, Ruiz de Galarreta M, Venkatesh A, et al
    Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.
    Gut. 2016 Nov 14. pii: gutjnl-2016-312268. doi: 10.1136/gutjnl-2016-312268.
    PubMed     Text format     Abstract available


    September 2016
  65. KUTTKAT N, Mohs A, Ohl K, Hooiveld G, et al
    Hepatic overexpression of cAMP-responsive element modulator alpha induces a regulatory T-cell response in a murine model of chronic liver disease.
    Gut. 2016 Sep 29. pii: gutjnl-2015-311119. doi: 10.1136/gutjnl-2015-311119.
    PubMed     Text format     Abstract available


  66. DAHEIM M, Lang S, Goeser T, Steffen HM, et al
    Real-world risk score for hepatocellular carcinoma risk prediction in CHBV: a validation outside of Asia.
    Gut. 2016 Sep 26. pii: gutjnl-2016-312993. doi: 10.1136/gutjnl-2016-312993.
    PubMed     Text format    


  67. CAROTENUTO P, Fassan M, Pandolfo R, Lampis A, et al
    Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers.
    Gut. 2016 Sep 12. pii: gutjnl-2016-312278. doi: 10.1136/gutjnl-2016-312278.
    PubMed     Text format     Abstract available


    August 2016
  68. HE GW, Gunther C, Kremer AE, Thonn V, et al
    PGAM5-mediated programmed necrosis of hepatocytes drives acute liver injury.
    Gut. 2016 Aug 26. pii: gutjnl-2015-311247. doi: 10.1136/gutjnl-2015-311247.
    PubMed     Text format     Abstract available



  69. Erratum: Acute kidney injury and acute-on-chronic liver failure classifications in prognosis assessment of patients with acute decompensation of cirrhosis.
    Gut. 2016;65:1394.
    PubMed     Text format    


    July 2016
  70. GRILLET F, Bayet E, Villeronce O, Zappia L, et al
    Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture.
    Gut. 2016 Jul 25. pii: gutjnl-2016-311447. doi: 10.1136/gutjnl-2016-311447.
    PubMed     Text format     Abstract available


  71. HACKSTEIN CP, Assmus LM, Welz M, Klein S, et al
    Gut microbial translocation corrupts myeloid cell function to control bacterial infection during liver cirrhosis.
    Gut. 2016 Jul 18. pii: gutjnl-2015-311224. doi: 10.1136/gutjnl-2015-311224.
    PubMed     Text format     Abstract available


    June 2016
  72. MALLAT A, Lotersztajn S
    Targeting cannabinoid receptors in hepatocellular carcinoma?
    Gut. 2016 Jun 24. pii: gutjnl-2016-312108. doi: 10.1136/gutjnl-2016-312108.
    PubMed     Text format    


  73. BHARDWAJ A, Kedarisetty CK, Vashishtha C, Bhadoria AS, et al
    Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
    Gut. 2016 Jun 13. pii: gutjnl-2016-311735. doi: 10.1136/gutjnl-2016-311735.
    PubMed     Text format     Abstract available


    May 2016
  74. CALO N, Ramadori P, Sobolewski C, Romero Y, et al
    Stress-activated miR-21/miR-21* in hepatocytes promotes lipid and glucose metabolic disorders associated with high-fat diet consumption.
    Gut. 2016 May 24. pii: gutjnl-2015-310822. doi: 10.1136/gutjnl-2015-310822.
    PubMed     Text format     Abstract available


  75. NJEI B, McCarty TR, Garcia-Tsao G
    Beta-blockers in patients with cirrhosis and ascites: type of beta-blocker matters.
    Gut. 2016 May 20. pii: gutjnl-2016-312129. doi: 10.1136/gutjnl-2016-312129.
    PubMed     Text format    


  76. BENOIT B, Pous C
    MAPping the Wnt pathway to hepatocellular carcinoma recurrence.
    Gut. 2016 May 17. pii: gutjnl-2016-311637. doi: 10.1136/gutjnl-2016-311637.
    PubMed     Text format    


  77. SUK KT, Mederacke I, Gwak GY, Cho SW, et al
    Opposite roles of cannabinoid receptors 1 and 2 in hepatocarcinogenesis.
    Gut. 2016 May 11. pii: gutjnl-2015-310212. doi: 10.1136/gutjnl-2015-310212.
    PubMed     Text format     Abstract available


  78. DUPARC T, Plovier H, Marrachelli VG, Van Hul M, et al
    Hepatocyte MyD88 affects bile acids, gut microbiota and metabolome contributing to regulate glucose and lipid metabolism.
    Gut. 2016 May 5. pii: gutjnl-2015-310904. doi: 10.1136/gutjnl-2015-310904.
    PubMed     Text format     Abstract available


  79. GENTLE L, Patanwala I
    Hepatology at a Glance.
    Gut. 2016 May 4. pii: gutjnl-2016-312068. doi: 10.1136/gutjnl-2016-312068.
    PubMed     Text format    


  80. LLOPIS M, Cassard AM, Wrzosek L, Boschat L, et al
    Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease.
    Gut. 2016;65:830-9.
    PubMed     Text format     Abstract available


    April 2016
  81. O'BRIEN A, China L
    Is human albumin solution really the best resuscitation fluid for patients with advanced cirrhosis?
    Gut. 2016 Apr 27. pii: gutjnl-2016-311999. doi: 10.1136/gutjnl-2016-311999.
    PubMed     Text format    


  82. JANSEN C, Bogs C, Krag A, Francque S, et al
    Sequential shear-wave elastography of liver and spleen rules out clinically significant portal hypertension in compensated advanced chronic liver disease.
    Gut. 2016 Apr 27. pii: gutjnl-2016-311955. doi: 10.1136/gutjnl-2016-311955.
    PubMed     Text format    


  83. KITSON MT, Pham A, Gordon A, Kemp W, et al
    High-dose vitamin D supplementation and liver histology in NASH.
    Gut. 2016;65:717-8.
    PubMed     Text format    


  84. MICHELOTTI GA, Tucker A, Swiderska-Syn M, Machado MV, et al
    Pleiotrophin regulates the ductular reaction by controlling the migration of cells in liver progenitor niches.
    Gut. 2016;65:683-92.
    PubMed     Text format     Abstract available


    March 2016
  85. GRIESMANN H, Drexel C, Milosevic N, Sipos B, et al
    Pharmacological macrophage inhibition decreases metastasis formation in a genetic model of pancreatic cancer.
    Gut. 2016 Mar 24. pii: gutjnl-2015-310049. doi: 10.1136/gutjnl-2015-310049.
    PubMed     Text format     Abstract available


  86. PICCININ E, Moschetta A
    Hepatic-specific PPARalpha-FGF21 action in NAFLD.
    Gut. 2016 Mar 18. pii: gutjnl-2016-311408. doi: 10.1136/gutjnl-2016-311408.
    PubMed     Text format    


  87. BRITO-AZEVEDO A, Perez RM, Coelho HS, Fernandes ES, et al
    Propranolol improves endothelial dysfunction in advanced cirrhosis: the 'endothelial exhaustion' hypothesis.
    Gut. 2016 Mar 16. pii: gutjnl-2016-311696. doi: 10.1136/gutjnl-2016-311696.
    PubMed     Text format    


  88. GARCIA-PRAS E, Gallego J, Coch L, Mejias M, et al
    Role and therapeutic potential of vascular stem/progenitor cells in pathological neovascularisation during chronic portal hypertension.
    Gut. 2016 Mar 16. pii: gutjnl-2015-311157. doi: 10.1136/gutjnl-2015-311157.
    PubMed     Text format     Abstract available


  89. CHEN J, Rajasekaran M, Xia H, Zhang X, et al
    The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/beta-catenin signalling pathway.
    Gut. 2016 Mar 3. pii: gutjnl-2015-310625. doi: 10.1136/gutjnl-2015-310625.
    PubMed     Text format     Abstract available


  90. KALAMBOKIS GN, Baltayiannis G, Christou L, Christodoulou D, et al
    Red signs and not severity of cirrhosis should determine non-selective beta-blocker treatment in Child-Pugh C cirrhosis with small varices: increased risk of hepatorenal syndrome and death beyond 6 months of propranolol use.
    Gut. 2016 Mar 2. pii: gutjnl-2016-311527. doi: 10.1136/gutjnl-2016-311527.
    PubMed     Text format    


  91. ICHOU L, Carbonell N, Rautou PE, Laurans L, et al
    Ascitic fluid TREM-1 for the diagnosis of spontaneous bacterial peritonitis.
    Gut. 2016;65:536-8.
    PubMed     Text format    


    February 2016
  92. JANSEN C, Bogs C, Verlinden W, Thiele M, et al
    Algorithm to rule out clinically significant portal hypertension combining Shear-wave elastography of liver and spleen: a prospective multicentre study.
    Gut. 2016 Feb 19. pii: gutjnl-2016-311536. doi: 10.1136/gutjnl-2016-311536.
    PubMed     Text format    


  93. COLOMBEL JF, Sands BE, Rutgeerts P, Sandborn W, et al
    The safety of vedolizumab for ulcerative colitis and Crohn's disease.
    Gut. 2016 Feb 18. pii: gutjnl-2015-311079. doi: 10.1136/gutjnl-2015-311079.
    PubMed     Text format     Abstract available


  94. SHI D, Zhang J, Zhou Q, Xin J, et al
    Quantitative evaluation of human bone mesenchymal stem cells rescuing fulminant hepatic failure in pigs.
    Gut. 2016 Feb 16. pii: gutjnl-2015-311146. doi: 10.1136/gutjnl-2015-311146.
    PubMed     Text format     Abstract available


  95. YANG Y, Lin X, Lu X, Luo G, et al
    Interferon-microRNA signalling drives liver precancerous lesion formation and hepatocarcinogenesis.
    Gut. 2016 Feb 9. pii: gutjnl-2015-310318. doi: 10.1136/gutjnl-2015-310318.
    PubMed     Text format     Abstract available


  96. WIESER V, Adolph TE, Enrich B, Kuliopulos A, et al
    Reversal of murine alcoholic steatohepatitis by pepducin-based functional blockade of interleukin-8 receptors.
    Gut. 2016 Feb 8. pii: gutjnl-2015-310344. doi: 10.1136/gutjnl-2015-310344.
    PubMed     Text format     Abstract available


  97. MARCHESI JR, Adams DH, Fava F, Hermes GD, et al
    The gut microbiota and host health: a new clinical frontier.
    Gut. 2016;65:330-9.
    PubMed     Text format     Abstract available


    January 2016
  98. POH Z, Shen L, Yang HI, Seto WK, et al
    Real-world risk score for hepatocellular carcinoma (RWS-HCC): a clinically practical risk predictor for HCC in chronic hepatitis B.
    Gut. 2016 Jan 19. pii: gutjnl-2015-310818. doi: 10.1136/gutjnl-2015-310818.
    PubMed     Text format    


  99. TILG H, Mathurin P
    Altered intestinal microbiota as a major driving force in alcoholic steatohepatitis.
    Gut. 2016 Jan 19. pii: gutjnl-2015-311014. doi: 10.1136/gutjnl-2015-311014.
    PubMed     Text format    


  100. STOCKDALE AJ, Phillips RO, Geretti AM
    The gamma-glutamyl transpeptidase to platelet ratio (GPR) shows poor correlation with transient elastography measurements of liver fibrosis in HIV-positive patients with chronic hepatitis B in West Africa. Response to: 'The gamma-glutamyl transpeptida
    Gut. 2016 Jan 4. pii: gutjnl-2015-311133. doi: 10.1136/gutjnl-2015-311133.
    PubMed     Text format    


    December 2015
  101. GARNELO M, Tan A, Her Z, Yeong J, et al
    Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma.
    Gut. 2015 Dec 15. pii: gutjnl-2015-310814. doi: 10.1136/gutjnl-2015-310814.
    PubMed     Text format     Abstract available


  102. TOVAR V, Cornella H, Moeini A, Vidal S, et al
    Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.
    Gut. 2015 Dec 11. pii: gutjnl-2015-309501. doi: 10.1136/gutjnl-2015-309501.
    PubMed     Text format     Abstract available


  103. HU HH, Liu J, Lin YL, Luo WS, et al
    The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B.
    Gut. 2015 Dec 7. pii: gutjnl-2015-310686. doi: 10.1136/gutjnl-2015-310686.
    PubMed     Text format     Abstract available


    October 2015
  104. FLECKEN T, Sarobe P
    Tim-3 expression in tumour-associated macrophages: a new player in HCC progression.
    Gut. 2015;64:1502-3.
    PubMed     Text format    


  105. YAN W, Liu X, Ma H, Zhang H, et al
    Tim-3 fosters HCC development by enhancing TGF-beta-mediated alternative activation of macrophages.
    Gut. 2015;64:1593-604.
    PubMed     Text format     Abstract available


    September 2015
  106. KLEIN S, Rick J, Lehmann J, Schierwagen R, et al
    Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.
    Gut. 2015 Sep 17. pii: gutjnl-2015-309600. doi: 10.1136/gutjnl-2015-309600.
    PubMed     Text format     Abstract available


    February 2015
  107. ARABZADEH A, Dupaul-Chicoine J, Breton V, Haftchenary S, et al
    Carcinoembryonic Antigen Cell Adhesion Molecule 1 long isoform modulates malignancy of poorly differentiated colon cancer cells.
    Gut. 2015 Feb 9. pii: gutjnl-2014-308781. doi: 10.1136/gutjnl-2014-308781.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: